Why the study?
Because β3-adrenoreceptors are expressed in human cardiac and vascular tissues, it is important to understand the beneficial or adverse cardiovascular effects of β3-agonists.
Do β-3 adrenergic receptor agonists improve cardiovascular outcomes and demonstrate safety in patients at high cardiovascular risk?
Design
Review
Key result
The β3-agonist mirabegron appears safe in patients at high cardiovascular risk but produces benefits on selected cardiovascular outcomes only at higher than standard doses.
Authors
Loading...
β3-agonists may be safe with dose-related benefits in high-risk patients; hypothesis-generating and should not yet change practice.
Do β-3 adrenergic receptor agonists improve cardiovascular outcomes and demonstrate safety in patients at high cardiovascular risk?
β3-adrenoreceptor agonists like mirabegron appear safe in high cardiovascular risk patients but may require higher than standard doses for cardiovascular benefits, warranting testing of more potent agonists like vibegron.
Balligand et al. (2023) conducted a review in cardiovascular diseases. β-3 adrenergic receptor agonists (e.g., mirabegron) was evaluated on cardiovascular outcomes. The β3-agonist mirabegron appears safe in patients at high cardiovascular risk but produces benefits on selected cardiovascular outcomes only at higher than standard doses.